NCT04504825 2026-03-17
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)
Alexion Pharmaceuticals, Inc.
Phase 3 Active not recruiting
Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Boston Medical Center
The Affiliated Hospital of Qingdao University
Vastra Gotaland Region
Yale University
Medical College of Wisconsin